Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index; 9 of the 36 sources its claims cite were checked for support.

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

Open access

Abstract

Previous studies have suggested that the gut microbiome influences the response to checkpoint inhibitors (CPIs) in patients with cancer. CBM588 is a bifidogenic live bacterial product that we postulated could augment CPI response through modulation of the gut microbiome. In this open-label, single-center study (NCT03829111), 30 treatment-naive patients with metastatic renal cell carcinoma with clear cell and/or sarcomatoid histology and intermediate- or poor-risk disease were randomized 2:1 to receive nivolumab and ipilimumab with or without daily oral CBM588, respectively. Stool metagenomic sequencing was performed at multiple timepoints. The primary endpoint to compare the relative abundance of Bifidobacterium spp. at baseline and at 12 weeks was not met, and no significant differences in Bifidobacterium spp. or Shannon index associated with the addition of CBM588 to nivolumab–ipilimumab were detected. Secondary endpoints included response rate, progression-free survival (PFS) and toxicity. PFS was significantly longer in patients receiving nivolumab–ipilimumab with CBM588 than without (12.7 months versus 2.5 months, hazard ratio 0.15, 95% confidence interval 0.05–0.47, P = 0.001). Although not statistically significant, the response rate was also higher in patients receiving CBM588 (58% versus 20%, P = 0.06). No significant difference in toxicity was observed between the study arms. The data suggest that CBM588 appears to enhance the clinical outcome in patients with metastatic renal cell carcinoma treated with nivolumab–ipilimumab. Larger studies are warranted to confirm this clinical observation and elucidate the mechanism of action and the effects on microbiome and immune compartments.

Overview

CoChat Summary

TL;DR

In a randomized phase 1 trial of 30 treatment-naive patients with metastatic renal cell carcinoma, adding the live bacterial product CBM588 to nivolumab–ipilimumab did not meet the primary microbiome endpoint of increasing Bifidobacterium spp. relative abundance at 12 weeks. However, CBM588 was associated with significantly longer progression-free survival and a numerically higher response rate without a significant toxicity difference.

Key findings

  • The primary endpoint was not met: no significant change in relative abundance of Bifidobacterium spp. from baseline to week 12 with CBM588, and no significant differences in Bifidobacterium spp. or Shannon index between arms.
  • Median PFS was 12.7 months with nivolumab–ipilimumab plus CBM588 versus 2.5 months without CBM588 (HR 0.15, 95% CI 0.05–0.47, P = 0.001).
  • Objective response rate was 58% (11/19) with CBM588 versus 20% (2/10) without (P = 0.06); disease control was 79% versus 40%.
  • Grade 3 or 4 treatment-attributable adverse events occurred in 52% of CBM588 patients versus 50% of control patients; no treatment-related deaths occurred.

Methods

  • Open-label, single-center, randomized phase 1 trial (NCT03829111) in 30 treatment-naive patients with metastatic renal cell carcinoma with clear cell and/or sarcomatoid histology and intermediate- or poor-risk IMDC disease; patients were randomized 2:1 to nivolumab–ipilimumab with or without daily oral CBM588 80 mg twice daily. One patient was deemed ineligible after treatment initiation, leaving 29 analyzed.
  • Stool metagenomic sequencing was performed at baseline and 12 weeks; peripheral blood was collected for circulating cytokine and immune cell analyses. Primary endpoint: relative abundance of Bifidobacterium spp. at baseline and 12 weeks. Secondary endpoints included response rate, PFS, and toxicity.
  • Analyses used Wilcoxon signed rank and Mann–Whitney U tests for microbiome/immune comparisons, Kaplan–Meier and log-rank tests for PFS/OS, and Fisher exact test for response rate.

Limitations

  • The paper states limitations including small sample size, lack of a placebo control, absence of baseline tumor genomic profiling, limited long-term follow-up for overall survival, no planned patient-reported outcomes, inability to account for dietary intake variations, no exclusion of recent antibiotic therapy, and inability to rule out that species other than Bifidobacterium drove clinical outcomes.
  • The paper also notes exploratory microbiome analyses were not adjusted for multiple comparisons and should be considered hypothesis generating.
  • Evident from the text: this is a single-center phase 1 study with a 2:1 randomization and no stratification factors, limiting generalizability and power for clinical endpoints.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41591-022-01694-6

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Efficacy outcomes in the treatment of patients with mRCC using nivolumab–ipilimumab with or without CBM588. a,b, Progression-free response (a) and overall survival (b). c–e, Best response by treatment arm (c), best change in target lesions from baseline (d), and a swimmers plot showing the response and survival characteristics (e). The data are from n = 29 patients (19 patients in the nivolumab–ipilimumab with CBM588 arm and 10 patients in the nivolumab–ipilimumab arm). The Kaplan–Meier log-rank test was used to compare survival between the two arms. Source data
Fig. 1 Efficacy outcomes in the treatment of patients with mRCC using nivolumab–ipilimumab with or without CBM588. a,b, Progression-free response (a) and overall survival (b). c–e, Best response by treatment arm (c), best change in target lesions from baseline (d), and a swimmers plot showing the response and survival characteristics (e). The data are from n = 29 patients (19 patients in the nivolumab–ipilimumab with CBM588 arm and 10 patients in the nivolumab–ipilimumab arm). The Kaplan–Meier log-rank test was used to compare survival between the two arms. Source dataCC BY · PubMed Central
Fig. 2 Microbiome assessment in patients with mRCC treated with nivolumab–ipilimumab with or without CBM588. a, Change in Bifidobacterium spp. from baseline to week 12 in patients by treatment arm, and by treatment arm and response. b,c, Decreases (b) and increases (c) in relative abundance of gut microbiome species associated with response to nivolumab–ipilimumab with CBM588. Analyses were performed using n = 52 stool samples from n = 26 patients (n = 18 patients in the nivolumab–ipilimumab with CBM588 arm and n = 8 patients in the nivolumab–ipilimumab arm). The Wilcoxon signed rank test was used to perform comparisons between two timepoints within the same treatment arm and the Mann–Whitney U test was used for comparisons between the two arms. Source data
Fig. 2 Microbiome assessment in patients with mRCC treated with nivolumab–ipilimumab with or without CBM588. a, Change in Bifidobacterium spp. from baseline to week 12 in patients by treatment arm, and by treatment arm and response. b,c, Decreases (b) and increases (c) in relative abundance of gut microbiome species associated with response to nivolumab–ipilimumab with CBM588. Analyses were performed using n = 52 stool samples from n = 26 patients (n = 18 patients in the nivolumab–ipilimumab with CBM588 arm and n = 8 patients in the nivolumab–ipilimumab arm). The Wilcoxon signed rank test was used to perform comparisons between two timepoints within the same treatment arm and the Mann–Whitney U test was used for comparisons between the two arms. Source dataCC BY · PubMed Central
Fig. 3 Changes in metabolic pathways in patients with mRCC treated with nivolumab–ipilimumab with or without CBM588. a,b Metabolic pathways with significantly different counts between baseline and week 12 in the nivolumab–ipilimumab with CBM588 arm (a) and the nivolumab–ipilimumab arm (b). Gut microbiome analyses were performed using n = 52 stool samples from n = 26 patients (n = 18 patients in the nivolumab–ipilimumab with CBM588 arm (n = 11 responders and n = 7 non-responders); and n = 8 patients (n = 7 non-responders and n = 1 responder) in the nivolumab–ipilimumab arm). The Wilcoxon signed rank test was used to compare metabolic pathways between the two timepoints. Source data
Fig. 3 Changes in metabolic pathways in patients with mRCC treated with nivolumab–ipilimumab with or without CBM588. a,b Metabolic pathways with significantly different counts between baseline and week 12 in the nivolumab–ipilimumab with CBM588 arm (a) and the nivolumab–ipilimumab arm (b). Gut microbiome analyses were performed using n = 52 stool samples from n = 26 patients (n = 18 patients in the nivolumab–ipilimumab with CBM588 arm (n = 11 responders and n = 7 non-responders); and n = 8 patients (n = 7 non-responders and n = 1 responder) in the nivolumab–ipilimumab arm). The Wilcoxon signed rank test was used to compare metabolic pathways between the two timepoints. Source dataCC BY · PubMed Central
Fig. 4 Changes in circulating cytokine levels from baseline to week 13 by treatment arm. Cytokine analyses were performed using n = 54 blood samples from n = 27 patients (n = 19 patients in the nivolumab–ipilimumab with CBM588 arm and n = 8 patients in the nivolumab–ipilimumab arm). Wilcoxon signed rank test was used to compare cytokine levels between the two timepoints. Source data
Fig. 4 Changes in circulating cytokine levels from baseline to week 13 by treatment arm. Cytokine analyses were performed using n = 54 blood samples from n = 27 patients (n = 19 patients in the nivolumab–ipilimumab with CBM588 arm and n = 8 patients in the nivolumab–ipilimumab arm). Wilcoxon signed rank test was used to compare cytokine levels between the two timepoints. Source dataCC BY · PubMed Central
Extended Data Fig. 1 CONSORT diagram. Patient CONSORT diagram.
Extended Data Fig. 1 CONSORT diagram. Patient CONSORT diagram.CC BY · PubMed Central
Extended Data Fig. 2 Assessment of Shannon diversity index by treatment arm and treatment arm and response. Assessment of Shannon diversity index by treatment arm (a) and treatment arm and response (b). Gut microbiome diversity was assessed using n=52 stool samples from n=26 patients (n=18 patients in nivolumab/ipilimumab with CBM588 arm [n=11 responders and n=7 non-responders]; and n=8 [n=7 non-responders and n=1 responder] patients in nivolumab/ipilimumab arm). Two-sided Mann-Whitney U test between nivolumab/ ipilimumab with CBM588 and nivolumab/ipilimumab. Two-sided Wilcoxon signed rank test between baseline and week 12. Shannon diversity index was calculated using the species-level abundance data (a,b). Source data
Extended Data Fig. 2 Assessment of Shannon diversity index by treatment arm and treatment arm and response. Assessment of Shannon diversity index by treatment arm (a) and treatment arm and response (b). Gut microbiome diversity was assessed using n=52 stool samples from n=26 patients (n=18 patients in nivolumab/ipilimumab with CBM588 arm [n=11 responders and n=7 non-responders]; and n=8 [n=7 non-responders and n=1 responder] patients in nivolumab/ipilimumab arm). Two-sided Mann-Whitney U test between nivolumab/ ipilimumab with CBM588 and nivolumab/ipilimumab. Two-sided Wilcoxon signed rank test between baseline and week 12. Shannon diversity index was calculated using the species-level abundance data (a,b). Source dataCC BY · PubMed Central
Extended Data Fig. 3 Assessment of fungal microbiome characteristics at order level. Fungal microbiome analyses were performed using n=52 stool samples from n=26 patients (n=18 patients in nivolumab/ipilimumab with CBM588 arm [n=11 responders and n=7 non- responders]; and n=8 [n=7 non-responders and n=1 responder] patients in nivolumab/ipilimumab arm). Taxa with a mean relative abundance less than 0.001 were summed as other. Source data
Extended Data Fig. 3 Assessment of fungal microbiome characteristics at order level. Fungal microbiome analyses were performed using n=52 stool samples from n=26 patients (n=18 patients in nivolumab/ipilimumab with CBM588 arm [n=11 responders and n=7 non- responders]; and n=8 [n=7 non-responders and n=1 responder] patients in nivolumab/ipilimumab arm). Taxa with a mean relative abundance less than 0.001 were summed as other. Source dataCC BY · PubMed Central
Extended Data Fig. 4 Differentially abundant taxa in patients who developed grade 3–4 adverse events (a) and those who did not develop grade 3–4 adverse events. Differentially abundant taxa in patients who developed grade 3–4 adverse events (a) and those who did not develop grade 3-4 adverse events (b). Analyses were performed using n=52 stool samples from n=18 patients in nivolumab/ipilimumab with CBM588 arm and n=8 patients in nivolumab/ipilimumab arm). Two-sided Mann-Whitney U test used to compare species across two groups. The length of the box plots represents the interquartile range (IQR) and the inside lines of the boxes represent the median. Source data
Extended Data Fig. 4 Differentially abundant taxa in patients who developed grade 3–4 adverse events (a) and those who did not develop grade 3–4 adverse events. Differentially abundant taxa in patients who developed grade 3–4 adverse events (a) and those who did not develop grade 3-4 adverse events (b). Analyses were performed using n=52 stool samples from n=18 patients in nivolumab/ipilimumab with CBM588 arm and n=8 patients in nivolumab/ipilimumab arm). Two-sided Mann-Whitney U test used to compare species across two groups. The length of the box plots represents the interquartile range (IQR) and the inside lines of the boxes represent the median. Source dataCC BY · PubMed Central
Extended Data Fig. 5 Changes in circulating cytokine levels from baseline to week 12 by treatment arm. Changes in circulating cytokine levels from baseline to week 12 by treatment arm. Cytokine analyses were performed using n=54 blood samples from n=27 patients (n=19 patients in nivolumab/ipilimumab with CBM588 arm and n=8 patients in nivolumab/ipilimumab arm). Wilcoxon signed rank test was used to compare cytokine levels across two timepoints. Source data
Extended Data Fig. 5 Changes in circulating cytokine levels from baseline to week 12 by treatment arm. Changes in circulating cytokine levels from baseline to week 12 by treatment arm. Cytokine analyses were performed using n=54 blood samples from n=27 patients (n=19 patients in nivolumab/ipilimumab with CBM588 arm and n=8 patients in nivolumab/ipilimumab arm). Wilcoxon signed rank test was used to compare cytokine levels across two timepoints. Source dataCC BY · PubMed Central
Extended Data Fig. 6 Changes in myeloid-derived suppressor cell and regulatory T cell populations by time in nivolumab/ipilimumab arm (a) and nivolumab/ipilimumab with CBM588 arm (b). Changes in myeloid-derived suppressor cell and regulatory T cell populations by time in nivolumab/ipilimumab arm (a) and nivolumab/ipilimumab with CBM588 arm (b). Immune cell populations were assessed in n=54 blood samples from n=27 patients (n=19 patients in nivolumab/ipilimumab with CBM588 arm and n=8 patients in nivolumab/ipilimumab arm). Wilcoxon test was used to compare immune cell populations at two timepoints. The length of the box plots represents the interquartile range (IQR) and the inside lines of the boxes represent the median. Whiskers (the vertical lines extending below and above each box) are used to represent the minimum and the maximum observation. Source data
Extended Data Fig. 6 Changes in myeloid-derived suppressor cell and regulatory T cell populations by time in nivolumab/ipilimumab arm (a) and nivolumab/ipilimumab with CBM588 arm (b). Changes in myeloid-derived suppressor cell and regulatory T cell populations by time in nivolumab/ipilimumab arm (a) and nivolumab/ipilimumab with CBM588 arm (b). Immune cell populations were assessed in n=54 blood samples from n=27 patients (n=19 patients in nivolumab/ipilimumab with CBM588 arm and n=8 patients in nivolumab/ipilimumab arm). Wilcoxon test was used to compare immune cell populations at two timepoints. The length of the box plots represents the interquartile range (IQR) and the inside lines of the boxes represent the median. Whiskers (the vertical lines extending below and above each box) are used to represent the minimum and the maximum observation. Source dataCC BY · PubMed Central

Verification

Claims the paper makes

5 Valid · 0 Not valid · 22 Not checked · 63 Own results and interpretations

41 more claims

Create a free account to see all 90 claims and to verify the 27 references still open.

See all claims — free account
  • Probably not a substantial claim. 35
  • It may state two separate claims as one. 15
  • The quote only partly states this claim. 1

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

7 more claims about this paper

Create a free account to see every claim other papers make about this one.

See all claims — free account

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 5

Citations

Cites

Show all 48 references

Cited by

See all 515

Metadata

Authors
Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., Hsu, J., Zengin, Z., Salgia, N., Salgia, S., Malhotra, J., Chawla, N., Chehrazi-Raffle, A., Muddasani, R., Gillece, J., Reining, L., Trent, J., Takahashi, M., Oka, K., Higashi, S., Kortylewski, M., Highlander, S. K., & Pal, S. K.
Affiliations
  • City Of Hope National Medical Center (US)
  • Translational Genomics Research Institute (US)
  • Miyarisan Pharmaceutical Co., Ltd. (Japan) (JP)
Corresponding author
  • Highlander, Sarah K.
  • Pal, Sumanta K.
Venue
Nature Medicine
Published
2022-02-28
Volume
28
Issue
4
Pages
704-712
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4214706689
Cited by
515
References
48
Citations by year
2026: 111 · 2025: 115 · 2024: 120 · 2023: 116 · 2022: 52
FWCI
42.10
Type
journal article
Language
en
Open access
Licence
Locations
  • Nature Medicine (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Gateway for Cancer Research
  • National Cancer Institute (P30CA033572)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
Keywords
nivolumab, ipilimumab, metastatic renal cell carcinoma, gut microbiota, Bifidobacterium, immune checkpoint inhibitors, combination immunotherapy, progression-free survival, response rate, stool metagenomics
MeSH terms
Ipilimumab, Nivolumab, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Dietary Supplements

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. https://app.cochat.ai/papers/10.1038/s41591-022-01694-6
The paper
Dizman, N., Meza, L., Bergerot, P., Alcantara, M., Dorff, T., Lyou, Y., Frankel, P., Cui, Y., Mira, V., Llamas, M., Hsu, J., Zengin, Z., Salgia, N., Salgia, S., Malhotra, J., Chawla, N., Chehrazi-Raffle, A., Muddasani, R., Gillece, J., . . . Pal, S. K. (2022). Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial. Nature Medicine. https://doi.org/10.1038/s41591-022-01694-6

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.